It was demonstrated previously that CSF1R inhibition using tyrosine kinase inhibitors can be used as a strategy to decrease microglia proliferation in neurodegenerative disease models, which led to beneficial effects such as reduced neuronal loss and behavioral deficits in mouse models of prion disease (5), tau pathology (10), and Aβ pathology (7, 9). Here, MAPT is linked to neurodegenerative disease.